Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.

Acta haematologica - 1 Jan 2014

Ringel Frauke, Kaeda Jaspal, Schwarz Michaela, Oberender Christian, Grille Peggy, Dörken Bernd, Marque Fanny, Manley Paul W, Radimerski Thomas, le Coutre Philipp

Abstract excerpt

Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to K562 Cells

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Myeloproliferative Disorders

Share to Quinoxalines

Share to STAT5 Transcription Factor

Source

Identifiers

PMID: 24504330
DOI: 10.1159/000356784

Genes

JAK2
BCR
SET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.PMID 24504330Read ↗

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.Semantic proximity Read ↗

Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.Semantic proximity Read ↗

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cellsSemantic proximity Read ↗

Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells.Semantic proximity Read ↗

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Semantic proximity Read ↗

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.Semantic proximity Read ↗

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.Semantic proximity Read ↗

Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.Semantic proximity Read ↗

In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.Semantic proximity Read ↗

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.Semantic proximity Read ↗

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.Semantic proximity Read ↗

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.